Immunosuppression Does Not Reduce Anti-tumor Efficacy _JACC.pdf (271.77 kB)
Immunosuppression Does Not Reduce Antitumor Efficacy
journal contribution
posted on 2019-02-15, 12:55 authored by TH CaoI read with great interest the paper by Mahmood et al. The authors conducted a very valuable and interesting study of 35 patients with immune checkpoint inhibitor (ICI)-associated myocarditis compared with 105 ICI-treated patients without myocarditis in a multicenter registry with 8 sites. The study found that myocarditis developed at a median of 34 days in patients receiving ICIs for the treatment of cancer. Moreover, the authors indicated that there were higher serum troponin levels and major adverse cardiac event rates with the use of lower steroid doses; higher steroid doses were associated with lower serum troponin levels and major adverse cardiac event rates in ICI-treated patients with myocarditis.
Funding
Dr. Cao is funded by the John and Lucille van Geest Foundation and the National Institute for Health Research Leicester Biomedical Research Centre.
History
Citation
J Am Coll Cardiol, 2018, 72 (6), p. 701Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular SciencesVersion
- AM (Accepted Manuscript)
Published in
J Am Coll CardiolPublisher
Elsevier for American College of Cardiologyeissn
1558-3597Acceptance date
2018-04-09Copyright date
2018Available date
2019-08-07Publisher DOI
Publisher version
https://www.sciencedirect.com/science/article/pii/S0735109718350769?via=ihubNotes
The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.Language
enAdministrator link
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC